

**IN THE CLAIMS**

1. (Currently Amended) A lipid-based dispersion comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent selected from the group consisting of

an antineoplastic agent selected from the group consisting of 6-diazo-5-oxo-L-norleucine, allopurinol sodium, azaserine, carzinophillin A, denopterin, dolasetron mesylate, edatrexate, eflornithine, erythropoietin, etoposide, fluconazole, melphalan, methotrexate, mycophenolic acid, pamidronate disodium, podophyllinic acid 2-ethylhydrazide, paclitaxel, pteropterin, streptonigrin, Tomudex® (N-((5-(((1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-L-glutamic acid), and ubenimex;

an immunosuppressant selected from the group consisting of azathioprine, basiliximab, bucillamine, daclizumab, muromonab-CD3, mycophenolic acid, mycophenolate mofetil and other mycophenolate esters, procodazole, Rho(D) immune globulin (human), romurtide, sirolimus, and ubenimex;

an analgesic selected from the group consisting of acetaminophen, aspirin, hydrocodone, pentosan polysulfate sodium, and phenyl salicylate,

an antiacne agent selected from the group consisting of erythromycin, isotretinoin, and tretinoin,

an antibiotic selected from the group consisting of amikin sulfate, azithromycin, cefazolin, cilastatin, imipenem, minocycline, and penicillin,

an antibacterial agent selected from the group consisting of 4-sulfanilamidosalicylic acid, acediasulfone, amfenac, amoxicillin, ampicillin, apalcillin, apicycline, aspoxicillin, aztreonam, bambermycin(s), biapenem, carbenicillin, carumonam, cefadroxil, cefamandole, cefatrizine, cebuperazone, cefclidin, cefdinir, cefditoren, cefepime, cefetamet, cefixime, cefinenoxime, cefminox, cefodizime, cefonicid, cefoperazone, ceforanide, cefotaxime, cefotetan, cefotiam, cefozopran, cefpimizole, cefpiramide, cefpirome, cefprozil, cefroxadine, ceftazidime, cefteram, ceftibuten, ceftriaxone, cefuzonam, cephalexin, cephaloglycin, cephalosporin C, cephradine, ciprofloxacin, clinafloxacin, cyclacillin, enoxacin, epicillin, flomoxef, grepafloxacin, hetacillin, imipenem, lomefloxacin, lymecycline, meropenem, moxalactam, mupirocin, nadifloxacin, norfloxacin, panipenem, pazufloxacin, penicillin N, pipemidic acid, quinacillin, ritipenem, salazosulfadimidine, sparfloxacin, succisulfone, sulfachrysoidine, sulfaloxic acid, teicoplanin, temafloxacin, temocillin, ticarcillin, tigemonam, tosufloxacin, trovafloxacin, and vancomycin;

an anticholinergic selected from the group consisting of hyoscyamine and oxybutynin;

an anticoagulant selected from the group consisting of dalteparin, heparin, and warfarin;

an antidyskinetic selected from the group consisting of amantidine, haloperidol, and tetrabenazine;

an antifibrotic selected from the group consisting of aprotinin, and desmopressin acetate;

an antifungal selected from the group consisting of amphotericin B, azaserine, a candicidin, itraconazole, lucensomycin, natamycin, and nystatin;

an antiglaucoma agent selected from the group consisting of brimonidine tartrate, brinzolamide, demecarium bromide, and levobetaxolol;

an anti-inflammatory agent selected from the group consisting of glucocorticoids, gold sodium thiomalate, 3-amino-4-hydroxybutyric acid, aceclofenac, alminoprofen, bromfenac, bumadizon, carprofen, diclofenac, diflunisal, enfenamic acid, etodolac, fendosal, flufenamic acid, gentisic acid, mefenamic acid, mefenamic acid, mesalamine, niflumic acid, olsalazine oxaceprol, S-adenosylmethionine, salsalate, sulfasalazine, and tolfenamic acid;

an antiosteoporotic agent selected from the group consisting of raloxifene, sodium fluoride, and teriparatide acetate;

an antipagetic agent selected from the group consisting of elcatonin, and tiludonic acid;

an anti-Parkinson's agent selected from the group consisting of benztropine mesylate, and biperiden;  
an antipsoratic agent selected from the group consisting of acitretin, anthralin, lonapalene, tacalcitol, and tazarotene;  
an antipyretic selected from the group consisting of acetaminosalol, bermoprofen, epirizole, morazone, and salacylamide;  
an antiseptic selected from the group consisting of chlorhexidine gluconate, metronidazole, and sodium sulfacetamide);  
an antithrombotic selected from the group consisting of argatroban, daltroban, iloprost, lamifiban, ozagrel, ridogrel, taprostene, and tirofiban;  
a calcium regulator selected from the group consisting of calcifediol, calcitonin, ipriflavone, and parathyroid hormone;  
a keratolytic selected from the group consisting of imiquimod, podofilox, and podophyllin; and a sclerosing agent selected from the group consisting of polidocanol, sodium ricinoleate, sodium tetradecyl sulfate, and tribenoside;

wherein the lipid based dispersions are liposomes and the mean particle size of the liposomes measured by dynamic light scattering is less than 100 nm.

2-4. (Cancelled)

5. (Original) The lipid-based dispersion of claim 1 wherein at least about 90% of the fatty-acid chains of the phosphatidyl choline comprise 16 or more carbon atoms.

6-8. (Cancelled)

9. (Original) The lipid-based dispersion of claim 1 wherein at least about 90% of the fatty-acid chains of the phosphatidyl choline comprise 18 or more carbon atoms.

10-11. (Cancelled)

12. (Previously presented) The lipid-based dispersion of claim 1 wherein at least 75% of the fatty-acid chains of the phosphatidyl choline comprise at least one double bond.

13. (Cancelled)

14. (Original) The lipid-based dispersion of claim 1 wherein the phosphatidyl choline is Soy-PC.

15. (Original) The lipid-based dispersion of claim 1 wherein the phosphatidyl choline is Egg-PC.

16. (Cancelled)

17. (Previously presented) The lipid-based dispersion of claim 1 that comprises less than 0.05% cholesterol.

18. (Previously presented) The lipid-based dispersion of claim 1 that comprises no cholesterol.

19-21. (Cancelled)

22. (Previously presented) The lipid-based dispersion of claim 1 wherein at least about 90% of the fatty-acid chains of the anionic phospholipid comprise 16 or more carbon atoms.

23-25. (Cancelled)

26. (Previously presented) The lipid-based dispersion of claim 1 wherein at least about 90% of the fatty-acid chains of the anionic phospholipid comprise 18 or more carbon atoms.

27-36. (Cancelled)

37. (Previously presented) The lipid-based dispersion of claim 1 wherein the liposomes have a melting temperature of 15°C.

38-41. (Cancelled)

42. (Previously presented) The lipid-based dispersion of claim 1 wherein the weight ratio of total lipid (phosphatidyl choline + anionic phospholipid) to therapeutic agent is greater than 20:1.

43-64. (Cancelled)